http://orcid.org/0000-0003-0306-9954
References
- Schmidt AF, Pearce LS, Wilkins JT, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;28:CD011748.
- Orringer CE, Jacobson TA, Saseen JJ, et al. Update on the use of PCSK9 inhibitors in adults: recommendations from an expert panel of the national lipid association. J Clin Lipidol. 2017;11(4):880–890.
- Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 inhibitors–the clinical benefit of lipid drugs. N Engl J Med. 2015;373(17):1588–1591.
- Ghadban R, Enezate T, Omran J, et al. Clinical outcomes of PCSK9Is: A meta-analysis of randomized clinical trials. Cardiovasc Diagn Ther. 2017;7(6):598–606.
- DuBroff R, De Lorgeril M. Cholesterol confusion and statin controversy. World J Cardiol. 2015;7:404–409.
- Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
- Kazi DS, Moran AE, Coxson PG. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. Jama. 2016;316:743–753.
- Arrieta A, Page TF, Veledar E, et al. Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives. PLoS ONE. 2017;12:e0169761.
- Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2017;137:338–350.
- Ford I, Murray H, McCowan C, et al. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of west of scotland coronary prevention study. Circulation. 2016;133:1073–1080.
- Hsue P Effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection (EPIC-HIV study) (EPIC-HIV). Clinicaltrials.gov Website. https://clinicaltrials.gov/ct2/show/NCT03207945?term=PCSK9&rank=7. [cited 2017 Feb 12]